

## **In The Claims**

1-44. (cancelled)

45. (currently amended) An anabolic medicament for treating a damaged tissue, ~~the tissue being characterized, when healthy, by a characteristic amino acid molar ratio for the healthy tissue per se, or for at least one peptide, polypeptide, or protein thereof,~~ the medicament comprising:

- a) at least one mucopolysaccharide extracellular matrix compound in an amount effective in the damaged tissue as anti-neo-inflammatory and anti-neo-angiogenetic agent,
- b) at least one polar surface active lipid; and
- c) ~~at least a~~ plurality of amino acids having an alpha carbon, the amino acids being present at a molar ratio which is characteristic of human breast tissue protein ~~corresponding to the characteristic amino acid molar ratio, and wherein~~ no more than 10% of the amino acids are ~~being~~ in dextroretary D-form.

46. (previously presented) The medicament according to claim 45, wherein said extracellular matrix compound is synthetically produced.

47. (previously presented) The medicament according to claim 45, wherein said extracellular matrix compound is obtained from a cellular or tissue source.

48. (previously presented) The medicament according to claim 45, wherein said polar surface active lipid is obtained from a cellular or tissue source.

49. (previously presented) The medicament according to claim 45, wherein said polar surface active lipid is synthetically produced.

50. (currently amended) The medicament according to claim 45, wherein ~~at least one of~~ said amino acids ~~is~~ are synthetically produced.

51. (currently amended) The medicament according to claim 45, wherein said ~~at least one of said~~ amino acids is are obtained from a cellular or tissue source.

52. (previously presented) The medicament according to claim 47, wherein said cellular or tissue source is selected from the group consisting of a cell membrane, a tissue and organ.

53. (previously presented) The medicament according to claim 45, wherein said extracellular matrix compound is selected from the group consisting of a glucosaminoglycan, a collagen, cartilage, chondroitin sulfate, a glycoprotein, and a protoglycan.

54. (previously presented) The medicament according to claim 45, wherein said polar surface active lipid is selected from the group consisting of a phospholipid, a glycolipid, and a lipoprotein.

55.-58. (canceled)

59. (currently amended) The medicament according to claim ~~58~~101, further comprising ~~amino acids present at a molar ratio corresponding to a characteristic molar ratio of amino acids in cyclosporin~~ methionine or betaine.

60. (currently amended) The medicament according to claim 59, wherein said medicament further comprises ~~amino acids present at the molar ratio corresponding to the characteristic molar ratio of amino acids in cyclosporin~~ are glycine, ~~L~~-alanine, ~~L~~-leucine, and ~~L~~-valine.

61.-64. (canceled)

65. (previously presented) The medicament according to claim 45, further comprising a sterile vehicle.

66. (previously presented) The medicament according to claim 48, wherein said cellular or tissue source is selected from the group consisting of a cell membrane, a tissue, and an organ.
67. (previously presented) The medicament according to claim 51, wherein said cellular or tissue source is selected from the group consisting of a cell membrane, a tissue, and an organ.
68. (previously presented) The medicament according to claim 49, wherein said polar surface active lipid is selected from a group consisting of a phospholipid, a glycolipid, and a lipoprotein.
69. (previously presented) The medicament according to claim 48, wherein said polar surface active lipid is selected from the group consisting of a phospholipid, a glycolipid, and lipoprotein.
70. (previously presented) The medicament according to claim 48, wherein at least one extracellular matrix compound, at least one polar surface active lipid, and at least one amino acid associate through a molecular bonding force.
71. (previously presented) The medicament according to claim 70, wherein said molecular bonding force is selected from the group consisting of electron affinity, van der Waals, and zwitterionic.
72. (previously presented) The medicament according to claim 59, wherein components of said medicament associate through a molecular bonding force.

73. (previously presented) The medicament according to claim 70, wherein said molecular bonding force is selected from the group consisting of electron affinity, van der Waals, and zwitterionic.

74. (previously presented) The medicament according to claim 45 further comprising at least one of (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3 oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; and (j) collagen.

75. (currently amended) The medicament according to claim ~~59~~ 101, further comprising at least one of (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3 oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; and (j) collagen.

76. (previously presented) The medicament according to claim 48, further comprising at least one of (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3 oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; and (j) collagen.

77. (previously presented) The medicament according to claim 73, further comprising at least one of (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3 oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; and (j) collagen.

78-96. (cancelled)

97. (currently amended) The medicament according to claim 45, ~~wherein said~~ further comprising ~~an amino acid is selected from the group consisting of~~ L-alanine, L-arginine, L-asparagine, L-cysteine, L-glutamic acid, L-glutamine, L-glutamate, L-proline, L-serine, glycine, L-threonine, L-tyrosine, L-aurine, L-gamma amino butyric acid, and or L-carnitine.

98. (currently amended) The medicament according to claim 45 further comprising a fatty acid selected from the group consisting of linoleic acid ~~or~~ and linolenic acid.

99. (currently amended) The medicament according to claim 45 ~~101~~, wherein the amino acids are present in a ratio of four moles L-leucine: two moles L-alanine: two moles L-valine: one mole methionine: one mole ~~[[L-]]~~gamma amino butyric acid: one mole ~~[[L-]]~~betaine: one mole glycine.

100. (currently amended) The medicament according to claim 99, further comprising a fatty acid selected from the group consisting of linoleic acid ~~or~~ and linolenic acid.

101. (previously presented) An anabolic medicament for treating a damaged tissue, the medicament comprising:

- a) at least one mucopolysaccharide extracellular matrix compound in an amount effective in the damaged tissue as anti-neo-inflammatory and anti-neo-angiogenetic agent,
- b) at least one polar surface active lipid; and
- c) a plurality of amino acids having an alpha carbon, the amino acids being present at a molar ratio which is characteristic of cyclosporin, wherein no more than 10% of the amino acids are in D-form, and the molar ratio comprises 2 moles L-valine: 4 moles L-leucine: 2-moles L-alanine.

102. (previously presented) An anabolic medicament for treating a damaged tissue, the medicament comprising:

- a) at least one mucopolysaccharide extracellular matrix compound in an amount effective in the damaged tissue as anti-neo-inflammatory and anti-neo-angiogenetic agent,
- b) at least one polar surface active lipid; and
- c) a plurality of amino acids having an alpha carbon, the amino acids being present at a molar ratio which is characteristic of healthy skin, wherein no more than 10% of the amino acids are in D-form, and the molar ratio of L-amino acids is 3 moles L-methionine: 16 moles L-proline: 13 moles L-tyrosine: 30 moles L-asparagine: 8 moles L-phenylalanine: 20 moles L-cysteine: 50 moles L-leucine: 38 moles L-serine: 29 moles L-arginine: 21 moles L-threonine: 21 moles L-valine: 3 moles L-histidine: 22 moles L-alanine: 14 moles L-isoleucine: 2 moles L-tryptophan: 46 moles L-glutamic acid: 12 moles L-lysine: 14 moles L-aspartic acid: 32 moles of L-glutamine.

103. (previously presented) An anabolic medicament for treating a damaged tissue, the medicament comprising:

- a) at least one mucopolysaccharide extracellular matrix compound in an amount effective in the damaged tissue as anti-neo-inflammatory and anti-neo-angiogenetic agent,
- b) at least one polar surface active lipid; and
- c) a plurality of amino acids having an alpha carbon, the amino acids being present at a molar ratio which is characteristic of fibrinogen, wherein no more than 10% of the amino acids are in D-form, and the molar ratio of L-amino acids is 15 moles L-methionine: 41 moles L-proline: 24 moles L-tyrosine: 30 moles L-asparagine: 28 moles L-phenylalanine: 13 moles L-cysteine: 51 moles L-leucine: 107 moles L-serine: 54 moles L-arginine: 59 moles L-threonine: 45 moles L-valine: 19 moles L-histidine: 37 moles L-alanine: 26 moles L-isoleucine: 19 moles L-tryptophan: 64 moles L-glutamic acid: 42 moles L-lysine: 50 moles L-aspartic acid: 30 moles L-glutamine.

104. (new) The medicament of claim 45, wherein the damaged tissue is selected from the group consisting of skin, eye, liver, gastro-intestinal, kidney, and lung.

105. (new) The medicament of claim 104, wherein the gastro-intestinal tissue is bowel tissue.

106. (new) The medicament of claim 105, wherein the bowel tissue is damaged from regional ileitis (Crohn's Disease), inflammatory bowel disease, ulcerative colitis, or mucous colitis.